Nephrogenic systemic fibrosis (NSF), a systemic fibrosing disorder, was first recognized in 1997 and described as a new disease in 2000. Initially considered a dermal disorder that occurred ...

Diagnosis Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Management Methylprednisolone, thalidomide and physical therapy. You have full access to this article via your institution.

Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at ...

Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at ...

Nature Reviews Nephrology - Factors that might affect risk of gadodiamide-related nephrogenic systemic fibrosis Skip to main content Thank you for visiting nature.com.

June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...

DALLAS, July 3 /PRNewswire/ -- The U. S. Food and Drug Administration recently warned that a commonly used contrast agent used to improve MRI images has been linked to a potentially fatal disease.

On Friday, May 20, and Saturday, May 21, 2011, Yale School of Medicine will host the 5th Annual Symposium on Nephrogenic Systemic Fibrosis and Allied Systemic Fibrosing Disorders. The two-day ...

The Food and Drug Administration (FDA) has approved 2 new macrocyclic gadolinium-based contrast agents (GBCAs), Elucirem ™ (gadopiclenol) and Vueway ™ (gadopiclenol), for use with magnetic ...

Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis in patients with kidney problems, according to a new study. NSF is a rare ...